Full Press Release Details
FRANKLIN LAKES, N.J. , May 22, 2013 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today the publication of its 2012 Sustainability Report . This is BD's fifth Sustainability Report and it continues to focus on the Company's shared value approach to sustainability.
"We believe the principles of shared value — creating value for shareholders by strengthening communities and addressing healthcare challenges of societies — are fundamental to our strategy," said Vincent A. Forlenza , Chairman, Chief Executive Officer and President. "For decades, BD's technologies and institutional knowledge have been applied for positive societal impact worldwide. We seek to further embed these capabilities more broadly in the Company to enhance our growth potential, societal impact and overall sustainability for decades to come."
This report aligns with version 3.1 of the Global Reporting Initiative (GRI) guidelines, and the Company has self-assessed it at GRI application level B. BD's 2012 Sustainability Report highlights its strategic priorities and performance in five key areas:
The new report also highlights the many awards, recognitions and affiliations that BD received in 2012 in the areas of sustainability, innovation, employer of choice, and environment, health and safety, including:
To view the full BD 2012 Sustainability Report online, visit www.bd.com/sustainability .
BD, a leading global medical technology company that manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving people's health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey , BD employs nearly 30,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit www.bd.com .
Contacts: Colleen T. White , Corporate Communications – 201-847-5369 [email protected]
Monique N. Dolecki , Investor Relations – 201-847-5378 [email protected]
SOURCE BD (Becton, Dickinson and Company)